top of page

Pioneering the Broadest Panel of Blood-Based Diagnostics

Sunbird Bio is developing blood-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of Alzheimer's disease, Parkinson's disease and other neurological disorders.
Sunbird Bio Icon

We are the first company to overcome the challenge of directly detecting and differentiating the specific proteins that aggregate in the brain and signal the presence of disease with a simple blood draw.

Neurodegenerative diseases such as Alzheimer's and Parkinson's are notoriously difficult to diagnose and treat, with devastating consequences for patients and their families. The growing availability of medications developed to slow the progression of Alzheimer’s disease, Parkinson’s disease and other neurological disorders increases the importance of accurate and timely diagnosis and monitoring for all patients.

 

Our APEX technology has demonstrated potential to provide researchers and clinicians with actionable information that is not available or accessible from current diagnostics.

APEX is the only technology platform currently in development that could help address the tremendous, growing need for more sensitive, reliable, non-invasive diagnostic tests to accelerate drug development and enhance patient care.

Sunbird Bio APex Technology.png

Our Technology

The validated APEX technology platform has demonstrated breakthrough potential to dramatically improve standards of care in Alzheimer's and Parkinson's disease, and other neurological disorders.

sunbird-bio-patients-1397344064.jpg

Our Focus

Neurological disorders are among the most prevalent illnesses worldwide, particularly as the global population is living longer and aging. A lack of accessible and reliable diagnostics is hindering diagnosis and treatment.

sunbird-bio-manufacturing-1405788565.jpg

About Us

Sunbird Bio is a leader in blood-based diagnostics for neurological diseases, driving paradigm-shifting success and improved patient outcomes.

Technology

Up to 40 million people worldwide are living with Alzheimer’s disease.

Due largely to diagnostic limitations, 50% of these individuals will never receive a referral to a neurologist or memory care specialist.

While early detection of Alzheimer’s disease has substantial clinical benefits and can empower affected individuals and their care partners to make proactive decisions about future treatment and care, currently available diagnostic tests may impede early diagnosis and monitoring of disease progression. 

It is estimated that the global economic burden of Alzheimer’s disease in 2019 was roughly $2 trillion, and by 2050, that burden will rise sharply to about $10 trillion and perhaps as high as $13.5 trillion, underscoring the critical need for improved diagnostics and treatment.

PET imaging, the current gold standard, is expensive, often inaccessible and not scalable

Molecular diagnostics use cerebrospinal fluid (CSF) obtained through painful, expensive and invasive procedures

Cognitive behavioral assessment is subjective, unreliable and can’t distinguish early stages of disease

sunbird-bio-patient-portrait-673354300.jpg

Data from a landmark study in people with Alzheimer’s disease show that the APEX test has over 90% correlation to gold-standard PET.

bottom of page